Potentiation of ApoE Function via Small Molecule Therapeutics



Recent studies further support the central role and interplay of amyloid-beta and neuroinflammation in the development of Alzheimer's disease.	Our focus is to develop effective, orally bioavailable, small molecule therapeutics to treat Alzheimer's disease.	Perhaps 30% of all Alzheimer's cases may be prevented though life style changes.

Learn about Madera BioSciences

Madera BioSciences in Rancho Santa Fe, California, is an early-stage company focused on identifying and developing small molecule therapeutics to treat Alzheimer's disease. Our strategy is to limit amyloid-beta (Aβ) mediated pathogenic effects and thereby change the natural course of the disease. Specifically, we are developing drug-like molecules to increase the amount and function of apolipoprotein E (ApoE).

Contact

Read More About Our Business Here